Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

All Conditions

Rare Diseases

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Ovarian Cancer

Ovarian Epithelial Cancer

Antineoplastic Agents

All Drugs and Chemicals

Micronutrients

Hematinics

Vitamins

Pemetrexed

Avelumab

Axitinib

Talazoparib

Enzyme Inhibitors

Folic Acid

Vitamin B Complex

Folic Acid Antagonists

Antineoplastic Agents, Immunological

Protein Kinase Inhibitors

Poly(ADP-ribose) Polymerase Inhibitors

Folinic Acid

Folate

Vitamin B9

Avelumab monotherapy as specified by sub-study protocol B9991001C

Avelumab in combination with CMP 001, Utomilumab or PF04518600 as specified by sub-study protocol B9991004C

Avelumab in combination with Loratanib as specified by sub-study protocol B9991005C

Avelumab monotherapy as specified by sub-study protocol B9991009C

Avelumab monotherapy or in combination with Pemetrexed as specified by sub-study protocol B9991023C

Avelumab in combination with Talazoparib as specified by sub-study B9991025C.

Avelumab in combination with Axitinib as specified by sub-study B9991027C.

Avelumab in combination with Talazoparib as specified by sub-study B9991032C.

Lorlatanib

CMP 001

Utomilumab

PF04518600

Pfizer CT.gov Call Center

This Master Protocol for Avelumab Continuation Sub-Studies is to provide continued treatment access, safety follow-up, and when applicable, overall survival follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer-sponsored Avelumab parent studies.

B9991046 is a master protocol that will consist of sub-studies from the following parent studies:

B9991001 - NCT02603432 B9991004 - NCT02554812 B9991005 - NCT02584634 B9991009 - NCT02580058 B9991023 - NCT03317496 B9991025 - NCT03330405 B9991027 - NCT03472560 B9991032 - NCT03565991

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Avelumab Master Protocol: An Open-label Continuation Study for Participants Continuing From Pfizer-sponsored Avelumab Clinical Studies.

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing	NCT05059522	Advanced Malign... NSCLC Ovarian Cancer Urothelial Canc... Solid Tumors	Avelumab Lorlatanib Talazoparib Pemetrexed Axitinib CMP 001 Utomilumab PF04518600	18 Years -	Pfizer
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing	NCT05059522	Advanced Malign... NSCLC Ovarian Cancer Urothelial Canc... Solid Tumors	Avelumab Lorlatanib Talazoparib Pemetrexed Axitinib CMP 001 Utomilumab PF04518600	18 Years -	Pfizer

Spots Global Cancer Trial Database for brca mutant tumors